PSA will likely be IST’d to reduce the cash burn. Expectations for a Merck deal for this indication have been virtually crashed as Merck did not make a move after the combo data was released. Look at the corporate presentation to get a sense where this is going. Big pharmaceutical decided to pass this once in a lifetime opportunity. Pulling a plug on Aim2Cerc today was a big tell — no interest at all. The company cannot afford running neither Aim2Cerc nor PSA. I’ve been saying this fo a long time. It was inevitable. Truth is that they can run only either NEO or HOT, not both. So, question is which one will they drop next.
News 
Market Data 
Discover 
